Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT 2: Vernakalant in Post-Cardiac Surgery AF/AFL
NCT00125320Phase 3Completed
- Sponsor
- Astellas Pharma
- Start
- Jun 2004
- Primary completion
- Feb 2007
- Modality
- Small Molecules
- Countries
- 6
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib) and atrial flutter (AFL) comparing Vernakalant with Placebo (2 arms). Primary endpoint: Effectiveness of RSD1235 (Conversion of atrial arrhythmia to sinus rhythm). Started Jun 2004; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on NCT00125320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00125320.